June Shot of the Month: The point Noskova had no business winning - WTA Tennis

TennisWorld No. 1 Aryna Sabalenka survived her toughest test of the tournament to beat Wimbledon champion Linda Noskova 7-6(1) 3-6 7-6(10-7) on Tuesday and reach the ‌U. S. Open semifinals for a sixth consecutive year. Defending champion Dabrowski of Ottawa into women's doubles semisThomson Reuters · Posted: Sep 08, 2026 4:08 PM EDT | Last Updated: September 9Listen to this articleEstimated 3 minutesThe audio version of this article is generated by AI-based technology. Mispronunciations can occur. We are working with our partners to continually review and improve the results. Aryna Sabalenka of Belarus celebrates a point against Linda Noskova of Czechia during their women's singles quarterfinal match on Day 10 of the 2026 U. S. Open in Queens, New York on Tuesday. (Al Bello/Getty Images)World No. 1 Aryna Sabalenka survived her toughest test of the tournament to beat Wimbledon champion Linda Noskova 7-6(1) 3-6 7-6(10-7) on Tuesday and reach the ‌U. S. Open semifinals for a sixth consecutive year.

AtlanticNova ScotiaNew BrunswickPrince Edward Island Newfoundland and LabradorCalgaryLethbridgeKitchenerGuelphNorthern OntarioSudburyNorth BaySault Ste. MarieTimminsOttawaKingstonBrockvillePembrokeReginaYorktonSaskatoonPrince AlbertTorontoWatchWeatherPeelHamiltonDurhamYorkHaltonNiagaraQueen's ParkToronto City HallIn PicturesVancouverVancouver IslandCanadaLocal SpotlightRoyal FamilyPoliticsNanosPower PlayQuestion PeriodFederal Election 2025WorldMideast ConflictRussia-Ukraine WarWatchLatestCaptured on CameraPoliticsLifestyleConsumerHealthExplainedEntertainmentTechnologyDeception DecodedAutosEnvironmentBusinessInflationReal EstateAutos

Severe sunburn increases the risk of developing melanoma, the most serious type of skin cancer. Credit: Olga Pankova/GettyA personalized mRNA vaccine reduced the risk of skin cancer returning or the recipient dying by 42% when used alongside an immunotherapy drug, according to long-awaited results for what could become the first approved mRNA vaccine for cancer. Oncologists regard a risk reduction of 10% as substantial, says Kristen Radford, an immunotherapist at Mater Research in Brisbane. A risk reduction of more than 40% “would send many researchers over the Moon”, adds Seth Cheetham, a geneticist at the University of Queensland in Brisbane, Australia. The personalized vaccine, called intismeran, is not designed to prevent skin cancer, or melanoma, from developing in the first place, but to stop it returning in people who have already undergone surgery to remove tumours. Anticipation for the trial results has been building since August, when the vaccine’s developers — Merck, based in Rahway, New Jersey, and Moderna, which is headquartered in Cambridge, Massachusetts — announced early positive results.

Informations complètes et à jour, compilées par Google Actualités à partir de sources d'actualité du monde entier